Markus Warmuth

passionate drug hunter, avid cyclist, world traveler

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Recent disappointing study results have sparked debate about the role of inflammation in CVD.

Our SVP and Head of Translational Biology Manav Korpal explains why it remains a valid target and why we believe the opportunity lies upstream with NEK7/NLRP3: https://t.co/bElOW4xU09

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Today, we report financial results and business highlights for the second quarter 2026.
CEO @markus_warmuth shares his perspective on our second quarter performance, recent milestones, and the continued momentum across our pipeline.
Read more: https://t.co/ptSbIkwnlw

[Markus Warmuth @markus_warmuth]

@MonteRosaTx @TrendsinBiotech Another cool publication from my band members @MonteRosaTx! Go QuEEN! Aye Oh!

[Markus Warmuth @markus_warmuth]

@zavaindar @SimonDBarnett @MonteRosaTx Thanks Zavain and Simon for your insightful talk while we are planning the next phase of incredible innovation!

[Markus Warmuth @markus_warmuth]

@MonteRosaTx @Novartis What a fantastic way to expand work with our partners at @Novartis. Together we will try to create better treatments for patients with immune-mediated diseases. QuEEN - degrading proteins, making medicines! Lets go @MonteRosaTx

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

At this year’s 2025 Stifel I&I Forum, our CEO, @markus_warmuth, will participate in a fireside chat and provide an overview of our I&I pipeline progress. Learn more: https://t.co/cPM3ePdxNM

[BiotechTV @BiotechTV]

𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐞𝐧𝐞𝐬: BiotechTV visited @MonteRosaTx in Boston, MA yesterday and learned about the work they are doing on molecular glue degraders. Scientist Katherine Jones showed us some of the equipment that makes it happen.

[Markus Warmuth @markus_warmuth]

40yrs LiveAid! 40 years ago at 6.41pm Queen came on stage for their legendary performance! When we had to name our @MonteRosaTx product engine we wanted it to represent greatness and doing the impossible. So we picked QuEEN! Best choice ever! Aye-Oh!

[Markus Warmuth @markus_warmuth]

40 years ago. “Glued” to TV! Aye-oh. Can’t wait for it to be 6.41pm again!

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

ICYMI: Last week, we published discoveries in a @ScienceMagazine cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs & our QuEEN™ discovery engine. https://t.co/305rlR9Jf0

[Markus Warmuth @markus_warmuth]

Over the last 6 years we @MonteRosaTx have pushed the limits on molecular glue degrader design. The term MGD didn’t even exist 6 years ago! Very proud of the team and exited about what the technology holds! Go QuEEN! Aye-Oh!

[Science Magazine @ScienceMagazine]

New research in Science greatly expands the potential target scope of molecular glues and should stimulate the development of new small molecules that can selectively target therapeutically relevant proteins for degradation.

Learn more in this week's issue: https://t.co/t9bwqHLkOz

[Markus Warmuth @markus_warmuth]

Our annual photo session “under the clock”. Amazing team, amazing science! Go QuEEN! Aye-oh!

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

2024 was a transformative year for Monte Rosa. We’re thrilled with the progress we’ve made and excited to announce our strategic priorities, goals, and milestones for 2025. Read more: https://t.co/y1eCaVeTw7

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Today, we announced that our CEO, Markus Warmuth, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 5:15 p.m. PST. We look forward to seeing you all in San Francisco! #JPM2025 https://t.co/iryKjF9iK8

[Markus Warmuth @markus_warmuth]

Congrats to our CDK2 team @MonteRosaTx. Beautiful work! Go QuEEN!

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

We’re presenting preclinical data at @SABCSSanAntonio on the potential of our highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader.
Learn more: https://t.co/VwypmKkQgh

[Markus Warmuth @markus_warmuth]

holiday season way of dealing with post game parking garage backup! Go FCB! @FCBayern

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Excellent explainer from @JuliaBauman2 on our paper - “Mining the Cereblon Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition” - showcasing our bold approach to tackling previously undruggable targets.

Thank you, Julia, for your insightful review!

[Markus Warmuth @markus_warmuth]

2 great presentations to take a look at! Go QuEEN! Ay-Oh!

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

ICYMI: Our team was on the ground for this week’s 7th #TPD and Induced Proximity Summit.

View our presentations to learn more about Monte Rosa’s work on CDK2 and Cyclin E1 #moleculargluedegraders, as well as our programs in GSPT1 and VAV1.

https://t.co/ZJduQNCKyM

[Monte Rosa Therapeutics, Inc @MonteRosaTx]

Attending the 7th #TPD and Induced Proximity Summit?

Nina Ilic-Widlund, Director of Oncology Biology, shares how we’re accelerating the rational discovery and design of #moleculargluedegraders, including CDK2 and Cyclin E1 #MGDs. Join us to learn more!

https://t.co/rgp3dPpbgc

[Markus Warmuth @markus_warmuth]

Such a pleasure to work with @FionaHMarshall  and the team at @Novartis to execute this agreement. For @MonteRosaTx, this agreement underscores our belief in the potential of molecular glue degraders, and we are encouraged by the possibilities that lie ahead.

[Fiona Marshall @FionaHMarshall]

I’m happy to share that Novartis and @MonteRosaTx have announced an exclusive global development and commercialization license agreement to advance molecular glue degraders. https://t.co/Pima2gEWMC